The Chinese company Shenzhen Kangtai Biological Products to produce candidate vaccines against coronavirus development of AstraZeneca. This is the first deal for the sale of the vaccine from COVID-19 in China, writes Reuters.
According to the agreement, Shenzhen Kangtai, one of the leading manufacturers of vaccines in China, by the end of the year will provide facilities to produce at least 100 million doses of an experimental vaccine AZD1222. Also, the Chinese side should be able to produce up to 200 million doses of vaccine. The financial side is not disclosed.
Currently, AstraZeneca has already signed contracts for the supply of AZD1222 the UK, USA, Netherlands, Germany, France and Italy. In addition, AstraZeneca has concluded with the Russian “R-Pharm” contract to manufacture vaccines against coronavirus, if clinical trials are successful.
According to the interim results of the ongoing clinical studies I/II phase COV001, which is held by the University of Oxford, after the introduction of AZD1222 develops enhanced immune response against the virus SARS-CoV-2. Thus, a single administration AZD1222 results in a fourfold increase of antibodies to thorn the squirrel virus SARS-CoV-2 95% of participants a month after vaccination. All participants noted the activation of T-cell immune response, which reached a peak by day 14 and persisted for 2 months after injection.